RSP Systems receives $2.6M grant for Raman spectroscopy-enabled device to monitor glucose

A noninvasive glucose monitor in development, based on a Raman spectroscopy method, has been awarded a $2.6 million grant.

Nov. 7, 2016

Noninvasive human diagnostics device maker RSP Systems (Odense, Denmark) has been awarded a $2.6 million (€2.4 million) grant to help commercialize the GlucoBeam noninvasive glucose monitor for diabetic patients, which is based on the company's critical-depth Raman spectroscopy technology. The grant is part of the European Union's Horizon 2020 framework for research and innovation.

GlucoBeam has been developed using Raman spectroscopy for glucose measurement in living tissue. The spectroscopic technique is commonly used in chemistry to provide a fingerprint by which molecules can be identified. Previous efforts to develop diagnostics for interstitial glucose in the skin were unsuccessful until the company produced unequivocal evidence that by selecting a specific skin depth, results could be correlated with blood glucose levels.

The company is integrating the technology into a noninvasive consumer glucose monitor with an analytical quality on par with current standards for invasive continuous glucose monitoring technologies. This integration will provide a truly noninvasive glucose monitor for diabetic patients.

For more information, please visit www.rspsystems.com.